The Targeted Pulse: Good News for Advanced CLL/SLL With BGB-16673 Receiving Fast ...
BGB-16673 received FDA fast-track designation for R/R CLL/SLL, potentially eligible for accelerated approval. Sonrotoclax combined with zanubrutinib showed improved responses in R/R CLL/SLL. Lurbinectedin vs topotecan data in ES-SCLC explored. Financial toxicity addressed through a tumor board. Clinicians discuss paclitaxel vs docetaxel in HER2-positive breast cancer.
Related Clinical Trials
Highlighted Terms
NCT05060016chronic lymphocytic leukemia (CLL)topotecansonrotoclax (BGB-11417)FDANCT04277637lurbinectedin (Zepzelca)Atrium Health Levine Cancer InstituteFred Hutch Cancer CenterNCT05006716docetaxelzanubrutinib (Brukinsa)HER2-positive breast cancerWake Forest School of MedicineYale School of MedicineEmory University School of MedicineBeiGeneUniversity of Washington School of MedicineBGB-16673small lymphocytic lymphoma (SLL)extensive-stage small cell lung cancer (ES-SCLC)Yale Cancer Centervenetoclax [Venclexta]NCT02566993paclitaxelNCT02454972obinutuzumab (Gazyva)
Related News
The Targeted Pulse: Good News for Advanced CLL/SLL With BGB-16673 Receiving Fast ...
BGB-16673 received FDA fast-track designation for R/R CLL/SLL, potentially eligible for accelerated approval. Sonrotoclax combined with zanubrutinib showed improved responses in R/R CLL/SLL. Lurbinectedin vs topotecan data in ES-SCLC explored. Financial toxicity addressed through a tumor board. Clinicians discuss paclitaxel vs docetaxel in HER2-positive breast cancer.